Home / Browse Journals & Books / Journal of Transplant Surgery / Archive
Select All | |
Research Article | Volume 2 Issue 1
Abstract: Limited data suggests that morbid obesity (Body Mass Index- BMI > 35 kg/m2) increases complications after left ventricular assist device (LVAD) implantation and after heart transplantation (HTx). We comprehensively compared LVAD and heart transplantation (HTx) outcomes in patients with and without morbid obesity.
| | |
Research Article | Volume 1 Issue 1
Abstract: We compare the 5-year outcomes of induction therapies with methylprednisolone (n = 58), basiliximab (n = 56) or alemtuzumab (n = 98) in patients with DGF. Maintenance was tacrolimus and mycophenolate with prednisone in methylprednisolone and basiliximab groups or without prednisone in alemtuzumab group. Protocol biopsies were performed in all patients.
Case Report | Volume 1 Issue 1
Abstract: We here report the case of successful orthotopic liver transplantation (LT) following acute liver failure (ALF) related to sinusoidal obstruction syndrome (SOS). This syndrome is one of the main causes of death early after bone marrow transplantation (BMT); LT seems to be an effective treatment of the most severe forms of SOS but no official recommendations exist about this subject. With this clinical case we would like to show that after careful patient selection and appropriate timing, LT for treatment of severe SOS is safe and effective.
Abstract: ESRD is a major health problem imposing great burden on the society. Dialysis either haemodialysis or peritoneal and transplantation are the two alternating treatment modalities. Transplantation became the preferred solution with lifetime monitoring immunosuppressive drugs.
Review Article | Volume 1 Issue 1
Abstract: Immunogenetic profiling of transplant recipients and pre-transplant tissue crossmatch between potential donor and recipient is mandatory in modern-day renal transplantation.
Abstract: Significant R&D investment is currently being made in the design of cost-effective devices for the manufacture of red blood cells (RBCs) from hematopoietic stem cells. If successful, such techniques will permit the for-profit manufacture of homologous transfusion products for alloimmunized patients, at a supply price comparable to the cost of the phenotyped transfusion units currently in use.
